- PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
- PROFESSOR | Pediatrics
- PROFESSOR | Environmental Medicine & Public Health
- Pulmonary Medicine
- Sleep Medicine
- Hospital Affiliation
- The Mount Sinai Hospital
- Mount Sinai-National Jewish Respiratory Institute 212-241-5656212-241-5656
In The News
Dr. Schachter discusses chronic obstructive pulmonary disease in The Daily News feature The Daily Check Up. View the PDF.
American Board of Internal Medicine
MD, New York University School of Medicine
Residency, Internal Medicine
Bellevue Hospital Center
Residency, Internal Medicine
Bellevue Hospital Center
Fellowship, Pulmonary Diseases
Yale University School of Medicine
ALA of Chicago
World COPD Day
The American Lung Association CONY
American Journal of Industrial Medicine
American College of Physicians
American College of Chest Physicians
Edward, Livingston Trudeau Fellow
American Lung Association
Environmental and occupational airway disease
Both clinical and in vitro studies are under way to investigate the clinical course, epideniology and mechanisms underlying airway diseases (asthma and bronchitis-like syndromes) that are seen in workers in a number of different industries. These industries employ organic compounds such as latex paper, wool, cotton, food products, and industrial wastes.
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
The purpose of this study is to evaluate the efficacy and safety of the Investigational (experimental not approved by the Food and Drug Administration FDA) study drug Fluticasone furoate (FF) /Umeclidinium (UMEC)/Vilanterol (VI) to see if it is safe and to see how effective it is...
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
The purpose of this study is to see if the investigational (experimental not approved by the Food and Drug Administration FDA) study drug Budesonide and Formoterol Fumarate Inhalation Aerosol Metered Dose Inhaler (BFF MDI), and Formoterol Fumarate Inhalation Aerosol Metered Dose ...
Schachter EN, Neuman T. Targeted therapies for the prevention of lung cancer. Drugs Today (Barc) 2007 Dec; 43(12): 897-936.
Schachter EN. The Good Doctor's Guide to Colds and Flu [Updated edition September 2006]. Harper Collins;.
Schachter EN. Cilomilast. Drugs Today (Barc) 2006 Apr; 42(4): 237-247.
Schachter EN, Zuskin E, Buck M, Witek TJ, Godbold J, Roy N, Castranova V, Whitmer M, Siegel PD, Bluhm EC. Airway responses to the inhalation of cotton dust and cotton bract extracts [Epub 2005 Sep 20]. Respiration 2006; 73(1): 41-47.
Rennard SI, Schachter N, Strek M, Reisner C, Rickard K, Zhu J, Amit O. Cilomilast for COPD: Results of a six month, placebo-controlled study of a potent, selective inhibitor of Phosphodiesterase 4. CHEST 2006; 129: 56-66.
Schachter EN, Zuskin E, Rienzi N, Goswami S, Castranova V, Siegel P, Whitmer M, Chung E. Pharmacological studies of wheat grain extract. Respiration 2004; 71: 276-283.
Zuskin E, Mustajbegovic J, Schachter EN, Kern J, Pavicic D, Deckovic-Vukres V, Pucarin-Cvetkovic J, Nola-Premec IA. Respiratory findings in pharmaceutical workers. Amer J Ind Med 2004; 46: 472-479.
Schachter EN. Tuberculosis: A Global Problem at our Doorstep. CHEST 2004; 126: 1724-1725.
Schachter EN. Byssinosis. In: Rosenstock L, Cullen M, Brodkin CA, Redlich CA, editors. Textbook of Clinical, Occupational and Environmental Medicine, 3rd Ed (2004). Philadelphia, Elsevier/Saunders ; pp309-321.
Schachter EN. Life and Breath (April 2003). [Paperback 2004]. New York, Broadway Books ;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Schachter did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.